124 related articles for article (PubMed ID: 24548695)
1. Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
Abou Daya K; Abu Daya H; Nasser Eddine M; Nahhas G; Nuwayri-Salti N
J Diabetes; 2015 Jan; 7(1):85-94. PubMed ID: 24548695
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
[TBL] [Abstract][Full Text] [Related]
3. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
4. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
Baraka A; AbdelGawad H
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):175-81. PubMed ID: 20133494
[TBL] [Abstract][Full Text] [Related]
5. Exposure to rosiglitazone, a PPAR-γ agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus.
Lie S; Hui M; McMillen IC; Muhlhausler BS; Posterino GS; Dunn SL; Wang KC; Botting KJ; Morrison JL
Am J Physiol Regul Integr Comp Physiol; 2014 Mar; 306(6):R429-37. PubMed ID: 24477540
[TBL] [Abstract][Full Text] [Related]
6. [Protective effect of rosiglitazone on myocardium in diabetic cardiomyopathy of rats].
Lu YL; Wang YN; Zhang L; Zhu L; Zhao JB; Wu H; Wang NC; Wang XF; Yu DL
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 May; 35(3):245-50. PubMed ID: 16764024
[TBL] [Abstract][Full Text] [Related]
7. Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
Guo Z; Qin Z; Zhang R; Li J; Yin Y
Eur J Pharmacol; 2012 Jun; 685(1-3):116-25. PubMed ID: 22542658
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
9. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.
Flaquer M; Lloberas N; Franquesa M; Torras J; Vidal A; Rosa JL; Herrero-Fresneda I; Grinyó JM; Cruzado JM
Life Sci; 2010 Jul; 87(5-6):147-53. PubMed ID: 20600147
[TBL] [Abstract][Full Text] [Related]
10. The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation.
Kilter H; Werner M; Roggia C; Reil JC; Schäfers HJ; Kintscher U; Böhm M
Diabetes Obes Metab; 2009 Nov; 11(11):1060-7. PubMed ID: 19732122
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration.
Lee TI; Chen YC; Kao YH; Hsiao FC; Lin YK; Chen YJ
Int J Cardiol; 2013 May; 165(2):299-307. PubMed ID: 21917327
[TBL] [Abstract][Full Text] [Related]
12. Effect of insulin and angiotensin II receptor subtype-1 antagonist on myocardial remodelling in rats with insulin-dependent diabetes mellitus.
Al Jaroudi WA; Nuwayri-Salti N; Usta JA; Zwainy DS; Karam CN; Bitar KM; Bikhazi AB
J Hypertens; 2005 Feb; 23(2):381-92. PubMed ID: 15662227
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
14. A study comparing the effects of rosiglitazone and/or insulin treatments on streptozotocin induced diabetic (type I diabetes) rat aorta and cavernous tissues.
Elçioğlu HK; Kabasakal L; Özkan N; Çelikel Ç; Ayanoğlu-Dülger G
Eur J Pharmacol; 2011 Jun; 660(2-3):476-84. PubMed ID: 21463620
[TBL] [Abstract][Full Text] [Related]
15. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
[TBL] [Abstract][Full Text] [Related]
17. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.
Duan SZ; Ivashchenko CY; Russell MW; Milstone DS; Mortensen RM
Circ Res; 2005 Aug; 97(4):372-9. PubMed ID: 16051889
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
[TBL] [Abstract][Full Text] [Related]
19. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
20. The role of rosiglitazone treatment in the modulation of islet hormones and hormone-like peptides: a combined in situ hybridization and immunohistochemical study.
Yildirim S; Bolkent S; Sundler F
J Mol Histol; 2008 Dec; 39(6):635-42. PubMed ID: 18998217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
